Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Norethindrone Acetate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR known ✓ | P06401 | 6/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 6/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 5/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 4/20 | 1.00 |
| ▸ | AR | P10275 | 4/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 4/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 2/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 0.70 |
| ▸ | ESR1 | P03372 | 3/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.70 |
| ▸ | MAOA | P21397 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Norethindrone Acetate SCHEMBL14360522 | 1.00 | CYP3A4 (1.00) | CYP3A4PGRABCB11CYP2C19AR | |
| Norethindrone Acetate SCHEMBL11321479 | 1.00 | CYP3A4 (1.00) | CYP3A4PGRABCB11CYP2C19AR | |
| Norethindrone Acetate SCHEMBL14074495 | 1.00 | CYP3A4 (1.00) | CYP3A4PGRABCB11CYP2C19AR | |
| Norethindrone Acetate SCHEMBL14577826 | 1.00 | CYP3A4 (1.00) | CYP3A4PGRABCB11CYP2C19AR | |
| Norethindrone Acetate SCHEMBL37530 | 1.00 | CYP3A4 (1.00) | CYP3A4PGRABCB11CYP2C19AR | |
| Norethindrone Acetate SCHEMBL16757740 | 0.96 | CYP3A4 (0.93) | CYP3A4PGRABCB11CYP2C19AR | |
| Norethindrone Acetate SCHEMBL8038659 | 0.94 | CYP3A4 (0.89) | CYP3A4PGRABCB11CYP2C19AR | |
| Norethindrone Acetate SCHEMBL691854 | 0.94 | CYP3A4 (0.89) | CYP3A4PGRABCB11CYP2C19AR | |
| SCHEMBL11291553 | 0.92 | CYP3A4 (0.85) | CYP3A4PGRABCB11CYP2C19AR | |
| SCHEMBL9473282 | 0.91 | CYP3A4 (0.84) | CYP3A4PGRABCB11CYP2C19AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2040683-B2 | PHARMACEUTICAL COMPOSITION CONTAINING A TETRAHYDROFOLIC ACID | BAYER IP GMBH (DE) | 2023-08-16 | — | — | EP | claimed |
| EP-2040683-B1 | PHARMACEUTICAL COMPOSITION CONTAINING A TETRAHYDROFOLIC ACID | BAYER IP GMBH (DE) | 2017-03-01 | — | — | EP | claimed |
| EP-2422774-B1 | Pharmaceutical composition containing a tetrahydrofolic acid | BAYER IP GMBH (DE) | 2015-08-12 | — | — | EP | claimed |
| US-20150065470-A1 | Steroid Sulfatase Inhibitor Regimen for the Treatment of Endometriosis | PREGLEM SA (CH) | 2015-03-05 | — | — | US | claimed |
| WO-2013150471-A1 | STEROID SULFATASE INHIBITOR REGIMEN FOR THE TREATMENT OF ENDOMETRIOSIS | PREGLEM SA (CH) | 2013-10-10 | — | — | WO | claimed |
| WO-2013150469-A1 | COMBINED USE OF A STEROID SULFATASE INHIBITOR FOR THE TREATMENT OF ENDOMETRIOSIS | PREGLEM SA (CH) | 2013-10-10 | — | — | WO | claimed |
| EP-2647379-A1 | Combined use of a steroid sulfatase inhibitor for the treatment of endometriosis | PregLem S.A. (CH) | 2013-10-09 | — | — | EP | claimed |
| EP-2647378-A1 | Steroid sulfatase inhibitor regimen for the treatment of endometriosis | PregLem S.A. (CH) | 2013-10-09 | — | — | EP | claimed |
| EP-2464331-A1 | STABILISED PARTICLES COMPRISING 5-METHYL-(6S)-TETRAHYDROFOLATE | Bayer Pharma Aktiengesellschaft (DE) | 2012-06-20 | — | — | EP | claimed |
| US-8076319-B2 | Treatment of conditions relating to hormone deficiencies by administration of progestins | BARR LABORATORIES, INC. (US) | 2011-12-13 | — | — | US | claimed |
| US-20040259851-A1 | Methods of administering estrogens and progestins | BARR LABORATORIES, INC. | 2004-12-23 | — | — | US | claimed |
| WO-2004091535-A2 | METHODS OF ADMINISTERING ESTROGENS AND PROGESTINS | BARR LABORATORIES, INC. (US) | 2004-10-28 | — | — | WO | claimed |
| EP-0136011-B2 | A method of hormonal treatment of peri-menopausal, menopausal and post-menopausal disorders and multi-preparation pack therefor | PRE JAY HOLDINGS LTD (CA) | 2004-06-09 | — | — | EP | claimed |
| US-20040072808-A1 | Treatment of conditions relating to hormone deficiencies by administration of progestins | BARR LABORATORIES, INC. | 2004-04-15 | — | — | US | claimed |
| EP-1390038-A2 | TREATMENT OF CONDITIONS RELATING TO HORMONE DEFICIENCIES BY ADMINISTRATION OF PROGESTINS | Endeavor Pharmaceuticals (US) | 2004-02-25 | — | — | EP | claimed |
| US-20030004145-A1 | Treatment of conditions relating to hormone deficiencies by administration of progestins | BARR LABORATORIES, INC. | 2003-01-02 | — | — | US | claimed |
| WO-2002092102-A2 | TREATMENT OF CONDITIONS RELATING TO HORMONE DEFICIENCIES BY ADMINISTRATION OF PROGESTINS | ENDEAVOR PHARMACEUTICALS (US) | 2002-11-21 | — | — | WO | claimed |
| US-RE36247-E | Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens | WOCO INVESTMENTS, LTD. (CA) | 1999-07-06 | — | — | US | claimed |
| EP-0136011-B1 | A method of hormonal treatment of peri-menopausal, menopausal and post-menopausal disorders and multi-preparation pack therefor | PRE JAY HOLDINGS LTD (CA) | 1997-01-22 | — | — | EP | claimed |
| US-4826831-A | Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens | PRE JAY HOLDINGS LIMITED (CA) | 1989-05-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150065470-A1 | Steroid Sulfatase Inhibitor Regimen for the Treatment of Endometriosis | SULT2A1, SULT1E1, STS | PGR 257/4885CYP3A4 199/4885ABCB11 1147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.